Open Orphan PLC Agreement signed with Empiric Logic (8397P)
15 Ottobre 2019 - 8:00AM
UK Regulatory
TIDMORPH
RNS Number : 8397P
Open Orphan PLC
15 October 2019
15 October 2019
Open Orphan plc
("Open Orphan" or the "Company")
Open Orphan signs agreement with Empiric Logic
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce it has signed
a new strategic collaboration agreement ("the Collaboration") with
Empiric Logic to build on the earlier work performed by Open Orphan
and complete the build out of Open Orphan's Health Data platform,
Europe's first rare disease, advocacy-led genomic database.
Empiric Logic, a leading managed software service company which
provides software to the Life Sciences, Pharma, Pharma Services and
Biotech sectors, will incorporate its propriety, privacy
preserving, and artificial intelligence enabled software into Open
Orphan's Health Data platform to aid the collection and management
capabilities of the software.
The Collaboration is the final stage in the completion of Open
Orphan's Genomic Health Data platform and will speed up its launch.
The platform builds on the genomic analysis, database architecture
know-how and prior professional experience between the founders of
Empiric Logic and Maurice Treacy, Chief Commercial Officer at Open
Orphan.
Cathal Friel, Chief Executive of Open Orphan commented:
"This is an exciting step towards the completion of our genomic
Health Data platform, and we are delighted to have Empiric on board
to help us quickly and securely become one of the largest databases
of rare disease patients in Europe."
Gareth O'Sullivan, CEO at Empiric Logic commented:
"Empiric Logic is delighted to be supporting the Open Orphan
team with the final steps of preparing the Genomic Health Data
platform to accept first data.
As part of the rollout of the Open Orphan database, it will be
making substantial use of our artificial intelligence capabilities,
such as for identification of rare-disease genetic mutations, but
also for the potential identification of patients for clinical
trials going forward."
Enquiries:
Open Orphan plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Dan Sherwen
Notes to Editors on Open Orphan:
Open Orphan plc is a European-focused, rare and orphan drug
consulting services platform. The Company intends to roll up a
number of orphan drug services business. Open Orphan has two data
driven digital platforms, a Genomic Health Data Platform, which is
establishing a rare disease database and a Virtual Rep platform
enabling pharmaceutical companies to engage key opinion leaders and
physicians. The Company is targeting rapid growth in one of the
fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
Notes to Editors on Empiric Logic:
Empiric Logic is a platform provider for health and genomics
data analysis. This platform uses proprietary analysis software to
automate key aspects of the collation, correlation and analysis of
complex health and genomics data.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRMIBFTMBABBBL
(END) Dow Jones Newswires
October 15, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venn Life Sciences (LSE:VENN)
Storico
Da Apr 2023 a Apr 2024
